29/10/2024 | Press release | Distributed by Public on 29/10/2024 11:47
Three Months Ended September 30, | Nine Months Ended September 30, | |||
($ in millions, except per share results) | 2024 | 2023 | 2024 | 2023 |
Net operating revenues |
$5,122
|
$5,066 |
$15,593
|
$15,169 |
Net income available to Tenet common shareholders |
$472
|
$101 |
$2,882
|
$367 |
Net income available to Tenet common shareholders per diluted share |
$4.89
|
$0.94 |
$29.27
|
$3.41 |
Adjusted EBITDA1
|
$978
|
$854 |
$2,947
|
$2,529 |
Adjusted diluted earnings per share1
|
$2.93 | $1.44 | $8.47 | $4.30 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
Ambulatory segment results($ in millions)
|
2024 | 2023 | 2024 | 2023 | ||||
Revenues | ||||||||
Net operating revenues | $1,139 | $941 |
$3,275
|
$2,788
|
||||
Same-facility system-wide net patient service revenues2
|
$1,895 | $1,744 | $5,516 | $5,133 | ||||
Volume Changes versus the Prior-Year Period | ||||||||
Same-facility system-wide surgical cases2
|
1.0 | % | 4.1 | % | 0.4 | % | 6.2 | % |
Same-facility system-wide surgical cases on same-business day basis2
|
(0.6) | % | 5.8 | % | (0.1) | % | 6.8 | % |
Adjusted EBITDA, Margins and NCI | ||||||||
Adjusted EBITDA |
$439
|
$370
|
$1,280
|
$1,080
|
||||
Adjusted EBITDA margin |
38.5%
|
39.3%
|
39.1%
|
38.7%
|
||||
Adjusted EBITDA less NCI |
$265
|
$233
|
$779
|
$678
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||
Hospital segment results($ in millions)
|
2024 | 2023 | 2024 | 2023 |
Revenues
|
||||
Net operating revenues
|
$3,983 | $4,125 |
$12,318
|
$12,381 |
Same-hospital net patient service revenues3
|
$3,383 |
$3,190
|
$10,298 |
$9,507
|
Same-Hospital Volume Changes versus the Prior-Year Period
|
||||
Admissions
|
5.2%
|
0.6%
|
4.9%
|
2.6%
|
Adjusted admissions4
|
2.7%
|
0.4%
|
2.3%
|
3.3%
|
Outpatient visits (including outpatient ER visits)
|
0.5%
|
(2.0)%
|
0.1%
|
(1.0)%
|
Emergency Room visits (inpatient and outpatient)
|
(0.2)%
|
(0.9)%
|
1.8%
|
1.3%
|
Hospital surgeries
|
0.6%
|
(0.7)%
|
-%
|
0.5%
|
Adjusted EBITDA | ||||
Adjusted EBITDA
|
$539 |
$484
|
$1,667
|
$1,449
|
Adjusted EBITDA margin
|
13.5%
|
11.7%
|
13.5%
|
11.7%
|
CONSOLIDATED ($ in millions, except per share amounts)
|
FY 2024 Outlook
|
Fourth Quarter
2024 Outlook
|
Net operating revenues |
$20,600 to $20,800
|
$5,007 to $5,207
|
Net income available to Tenet common stockholders |
$3,093 to $3,193
|
$211 to $311
|
Adjusted EBITDA |
$3,900 to $4,000
|
$953 to $1,053
|
Adjusted EBITDA margin |
18.9% to 19.2%
|
19.0% to 20.2%
|
Diluted income per common share |
$31.56 to $32.58
|
$2.20 to $3.24
|
Adjusted net income |
$1,090 to $1,150
|
$258 to $318
|
Adjusted diluted earnings per share |
$11.12 to $11.73
|
$2.69 to $3.31
|
Equity in earnings of unconsolidated affiliates | $260 to $270 | $78 to $88 |
Depreciation and amortization |
$820 to $840
|
$195 to $215
|
Interest expense |
$820 to $830
|
$197 to $207
|
Income tax expense5
|
$1,185 to $1,215
|
$84 to $114
|
Net income available to NCI |
$835 to $855
|
$225 to $245
|
Weighted average diluted common shares |
~98 million
|
~96 million
|
NCI cash distributions | $725 to $775 | |
Net cash provided by operating activities6
|
$1,775 to $2,125
|
|
Adjusted net cash provided by operating activities6
|
$1,950 to $2,250
|
|
Capital expenditures |
$800 to $900
|
|
Free cash flow6
|
$975 to $1,225
|
|
Adjusted free cash flow6
|
$1,150 to $1,350
|
Ambulatory Segment($ in millions)
|
FY 2024 Outlook
|
Net operating revenues | $4,375 to $4,425 |
Adjusted EBITDA | $1,760 to $1,800 |
NCI | $690 to $710 |
Adjusted EBITDA less NCI | $1,070 to $1,090 |
Changes versus prior year7:
|
|
Surgical cases volumes | Up 0.0% to 1.0% |
Net revenues per surgical case | Up 6.0% to 7.0% |
Hospital Segment ($ in millions)
|
FY 2024 Outlook
|
Net operating revenues | $16,225 to $16,375 |
Adjusted EBITDA | $2,140 to $2,200 |
NCI | $145 to $145 |
Changes versus prior year7:
|
|
Inpatient admissions | Up 4.0% to 5.0% |
Adjusted admissions | Up 1.5% to 2.5% |
Investor Contact | Media Contact |
Will McDowell | Robert Dyer |
469-893-2387 | 469-893-2640 |
[email protected] |
Description | Page |
12
|
|
(Dollars in millions, except per share amounts) | Three Months Ended September 30, | |||||||||
2024 | % | 2023 | % | Change | ||||||
Net operating revenues | $ | 5,122 | 100.0 | % | $ | 5,066 | 100.0 | % | 1.1 | % |
Grant income | 4 | 0.1 | % | 3 | 0.1 | % | 33.3 | % | ||
Equity in earnings of unconsolidated affiliates | 62 | 1.2 | % | 51 | 1.0 | % | 21.6 | % | ||
Operating expenses: | ||||||||||
Salaries, wages and benefits | 2,218 | 43.3 | % | 2,288 | 45.2 | % | (3.1) | % | ||
Supplies | 881 | 17.2 | % | 877 | 17.3 | % | 0.5 | % | ||
Other operating expenses, net | 1,111 | 21.6 | % | 1,101 | 21.7 | % | 0.9 | % | ||
Depreciation and amortization | 209 | 4.1 | % | 224 | 4.5 | % | ||||
Impairment and restructuring charges, and acquisition-related costs | 19 | 0.4 | % | 47 | 0.9 | % | ||||
Litigation and investigation costs | 9 | 0.2 | % | 14 | 0.3 | % | ||||
Net losses (gains) on sales, consolidation and deconsolidation of facilities | (348) | (6.8) | % | 1 | - | % | ||||
Operating income | 1,089 | 21.3 | % | 568 | 11.2 | % | ||||
Interest expense | (202) | (227) | ||||||||
Other non-operating income, net | 35 | 4 | ||||||||
Income before income taxes | 922 | 345 | ||||||||
Income tax expense | (241) | (79) | ||||||||
Net income | 681 | 266 | ||||||||
Less: Net income available to noncontrolling interests | 209 | 165 | ||||||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 472 | $ | 101 | ||||||
Earnings per share available to Tenet Healthcare Corporation common shareholders: | ||||||||||
Basic | $ | 4.93 | $ | 0.99 | ||||||
Diluted | $ | 4.89 | $ | 0.94 | ||||||
Weighted average shares and dilutive securities outstanding (in thousands): | ||||||||||
Basic | 95,665 | 101,544 | ||||||||
Diluted | 96,652 | 104,425 |
(Dollars in millions, except per share amounts) | Nine Months Ended September 30, | |||||||||
2024 | % | 2023 | % | Change | ||||||
Net operating revenues | $ | 15,593 | 100.0 | % | $ | 15,169 | 100.0 | % | 2.8 | % |
Grant income | 9 | 0.1 | % | 14 | 0.1 | % | (35.7) | % | ||
Equity in earnings of unconsolidated affiliates | 182 | 1.2 | % | 155 | 1.0 | % | 17.4 | % | ||
Operating expenses: | ||||||||||
Salaries, wages and benefits | 6,707 | 43.0 | % | 6,831 | 45.0 | % | (1.8) | % | ||
Supplies | 2,717 | 17.4 | % | 2,659 | 17.5 | % | 2.2 | % | ||
Other operating expenses, net | 3,413 | 22.0 | % | 3,319 | 21.9 | % | 2.8 | % | ||
Depreciation and amortization | 625 | 4.0 | % | 654 | 4.3 | % | ||||
Impairment and restructuring charges, and acquisition-related costs | 75 | 0.5 | % | 84 | 0.6 | % | ||||
Litigation and investigation costs | 18 | 0.1 | % | 28 | 0.2 | % | ||||
Net gains on sales, consolidation and deconsolidation of facilities | (2,906) | (18.6) | % | (12) | (0.1) | % | ||||
Operating income | 5,135 | 32.9 | % | 1,775 | 11.7 | % | ||||
Interest expense | (623) | (674) | ||||||||
Other non-operating income, net | 89 | 8 | ||||||||
Loss from early extinguishment of debt | (8) | (11) | ||||||||
Income before income taxes | 4,593 | 1,098 | ||||||||
Income tax expense | (1,101) | (243) | ||||||||
Net income | 3,492 | 855 | ||||||||
Less: Net income available to noncontrolling interests | 610 | 488 | ||||||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 2,882 | $ | 367 | ||||||
Earnings per share available to Tenet Healthcare Corporation common shareholders: | ||||||||||
Basic | $ | 29.56 | $ | 3.60 | ||||||
Diluted | $ | 29.27 | $ | 3.41 | ||||||
Weighted average shares and dilutive securities outstanding (in thousands): | ||||||||||
Basic | 97,505 | 101,869 | ||||||||
Diluted | 98,518 | 105,021 |
(Dollars in millions) | September 30, | December 31, | ||
2024 | 2023 | |||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $ | 4,094 | $ | 1,228 |
Accounts receivable | 2,598 | 2,914 | ||
Inventories of supplies, at cost | 356 | 411 | ||
Assets held for sale | 20 | 775 | ||
Other current assets | 1,691 | 1,839 | ||
Total current assets
|
8,759 | 7,167 | ||
Investments and other assets | 3,064 | 3,157 | ||
Deferred income taxes | 36 | 77 | ||
Property and equipment, at cost, less accumulated depreciation and amortization | 5,552 | 6,236 | ||
Goodwill | 10,588 | 10,307 | ||
Other intangible assets, at cost, less accumulated amortization | 1,373 | 1,368 | ||
Total assets
|
$ | 29,372 | $ | 28,312 |
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current portion of long-term debt | $ | 95 | $ | 120 |
Accounts payable | 1,265 | 1,408 | ||
Accrued compensation and benefits | 879 | 930 | ||
Professional and general liability reserves | 286 | 254 | ||
Accrued interest payable | 248 | 200 | ||
Liabilities held for sale | 12 | 69 | ||
Income tax payable | 826 | 23 | ||
Other current liabilities | 1,927 | 1,756 | ||
Total current liabilities
|
5,538 | 4,760 | ||
Long-term debt, net of current portion | 12,776 | 14,882 | ||
Professional and general liability reserves | 855 | 792 | ||
Defined benefit plan obligations | 308 | 335 | ||
Deferred income taxes | 260 | 326 | ||
Other long-term liabilities | 1,560 | 1,709 | ||
Total liabilities
|
21,297 | 22,804 | ||
Commitments and contingencies | ||||
Redeemable noncontrolling interests in equity of consolidated subsidiaries | 2,649 | 2,391 | ||
Equity: | ||||
Shareholders' equity: | ||||
Common stock | 8 | 8 | ||
Additional paid-in capital | 4,849 | 4,834 | ||
Accumulated other comprehensive loss | (175) | (181) | ||
Retained earnings (accumulated deficit) | 2,690 | (192) | ||
Common stock in treasury, at cost | (3,538) | (2,861) | ||
Total shareholders' equity | 3,834 | 1,608 | ||
Noncontrolling interests
|
1,592 | 1,509 | ||
Total equity | 5,426 | 3,117 | ||
Total liabilities and equity
|
$ | 29,372 | $ | 28,312 |
(Dollars in millions) | Nine Months Ended | |||
September 30, | ||||
2024 | 2023 | |||
Net income | $ | 3,492 | $ | 855 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||
Depreciation and amortization | 625 | 654 | ||
Deferred income tax expense (benefit) | (29) | 75 | ||
Stock-based compensation expense | 52 | 48 | ||
Impairment and restructuring charges, and acquisition-related costs | 75 | 84 | ||
Litigation and investigation costs | 18 | 28 | ||
Net gains on sales, consolidation and deconsolidation of facilities | (2,906) | (12) | ||
Loss from early extinguishment of debt | 8 | 11 | ||
Equity in earnings of unconsolidated affiliates, net of distributions received | (9) | 5 | ||
Amortization of debt discount and debt issuance costs | 21 | 25 | ||
Net gains from the sale of investments and long-lived assets | (2) | (25) | ||
Other items, net | (3) | (1) | ||
Changes in cash from operating assets and liabilities: | ||||
Accounts receivable | 183 | 31 | ||
Inventories and other current assets | 10 | (49) | ||
Income taxes | 821 | (46) | ||
Accounts payable, accrued expenses and other current liabilities | 123 | (38) | ||
Other long-term liabilities | 18 | 10 | ||
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (119) | (105) | ||
Net cash provided by operating activities | 2,378 | 1,550 | ||
Cash flows from investing activities: | ||||
Purchases of property and equipment | (601) | (543) | ||
Purchases of businesses or joint venture interests, net of cash acquired | (524) | (110) | ||
Proceeds from sales of facilities and other assets | 4,965 | 38 | ||
Proceeds from sales of marketable securities and long-term investments | 25 | 40 | ||
Purchases of marketable securities and long-term investments | (46) | (54) | ||
Other items, net | (18) | (7) | ||
Net cash provided by (used in) investing activities | 3,801 | (636) | ||
Cash flows from financing activities: | ||||
Repayments of borrowings | (2,212) | (1,478) | ||
Proceeds from borrowings | 16 | 1,368 | ||
Repurchases of common stock | (672) | (90) | ||
Debt issuance costs | - | (16) | ||
Distributions paid to noncontrolling interests | (496) | (425) | ||
Proceeds from the sale of noncontrolling interests | 13 | 37 | ||
Purchases of noncontrolling interests | (127) | (127) | ||
Advances from managed care payers | 342 | - | ||
Repayments of advances from managed care payers | (160) | - | ||
Other items, net | (17) | 13 | ||
Net cash used in financing activities | (3,313) | (718) | ||
Net increase in cash and cash equivalents | 2,866 | 196 | ||
Cash and cash equivalents at beginning of period | 1,228 | 858 | ||
Cash and cash equivalents at end of period | $ | 4,094 | $ | 1,054 |
Supplemental disclosures: | ||||
Interest paid, net of capitalized interest | $ | (555) | $ | (589) |
Income tax payments, net | $ | (308) | $ | (212) |
Three Months Ended | Nine Months Ended | |||||||
September 30, | September 30, | |||||||
(Dollars in millions) | 2024 | 2023 | 2024 | 2023 | ||||
Net operating revenues: | ||||||||
Ambulatory Care | $ | 1,139 | $ | 941 | $ | 3,275 | $ | 2,788 |
Hospital Operations and Services | 3,983 | 4,125 | 12,318 | 12,381 | ||||
Total | $ | 5,122 | $ | 5,066 | $ | 15,593 | $ | 15,169 |
Equity in earnings of unconsolidated affiliates: | ||||||||
Ambulatory Care | $ | 61 | $ | 50 | $ | 175 | $ | 149 |
Hospital Operations and Services | 1 | 1 | 7 | 6 | ||||
Total | $ | 62 | $ | 51 | $ | 182 | $ | 155 |
Adjusted EBITDA: | ||||||||
Ambulatory Care | $ | 439 | $ | 370 | $ | 1,280 | $ | 1,080 |
Hospital Operations and Services | 539 | 484 | 1,667 | 1,449 | ||||
Total | $ | 978 | $ | 854 | $ | 2,947 | $ | 2,529 |
Adjusted EBITDA margins: | ||||||||
Ambulatory Care | 38.5 | % | 39.3 | % | 39.1 | % | 38.7 | % |
Hospital Operations and Services | 13.5 | % | 11.7 | % | 13.5 | % | 11.7 | % |
Total | 19.1 | % | 16.9 | % | 18.9 | % | 16.7 | % |
Capital expenditures: | ||||||||
Ambulatory Care | $ | 28 | $ | 20 | $ | 65 | $ | 58 |
Hospital Operations and Services | 188 | 156 | 536 | 485 | ||||
Total | $ | 216 | $ | 176 | $ | 601 | $ | 543 |
Three Months Ended | Nine Months Ended | |||||||
September 30, | September 30, | |||||||
(Dollars in millions, except per share amounts) | 2024 | 2023 | 2024 | 2023 | ||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 472 | $ | 101 | $ | 2,882 | $ | 367 |
Less: | ||||||||
Impairment and restructuring charges, and acquisition-related costs
|
(19) | (47) | (75) | (84) | ||||
Litigation and investigation costs | (9) | (14) | (18) | (28) | ||||
Net gains (losses) on sales, consolidation and deconsolidation of facilities | 348 | (1) | 2,906 | 12 | ||||
Loss from early extinguishment of debt | - | - | (8) | (11) | ||||
Tax and noncontrolling interests impact of above items | (130) | 10 | (755) | 17 | ||||
Adjusted net income available to common shareholders | $ | 282 | $ | 153 | $ | 832 | $ | 461 |
Diluted earnings per share | $ | 4.89 | $ | 0.94 | $ | 29.27 | $ | 3.41 |
Less: | ||||||||
Impairment and restructuring charges, and acquisition-related costs
|
(0.20) | (0.45) | (0.76) | (0.80) | ||||
Litigation and investigation costs | (0.09) | (0.13) | (0.19) | (0.27) | ||||
Net gains (losses) on sales, consolidation and deconsolidation of facilities | 3.60 | (0.01) | 29.50 | 0.12 | ||||
Loss from early extinguishment of debt | - | - | (0.08) | (0.10) | ||||
Tax and noncontrolling interests impact of above items | (1.35) | 0.09 | (7.67) | 0.16 | ||||
Adjusted diluted earnings per share | $ | 2.93 | $ | 1.44 | $ | 8.47 | $ | 4.30 |
Weighted average basic shares outstanding (in thousands) | 95,665 | 101,544 | 97,505 | 101,869 | ||||
Weighted average dilutive shares outstanding (in thousands) | 96,652 | 104,425 | 98,518 | 105,021 |
Three Months Ended | Nine Months Ended | |||||||
September 30, | September 30, | |||||||
(Dollars in millions) | 2024 | 2023 | 2024 | 2023 | ||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 472 | $ | 101 | $ | 2,882 | $ | 367 |
Less: | ||||||||
Net income available to noncontrolling interests | (209) | (165) | (610) | (488) | ||||
Net income | 681 | 266 | 3,492 | 855 | ||||
Income tax expense | (241) | (79) | (1,101) | (243) | ||||
Loss from early extinguishment of debt | - | - | (8) | (11) | ||||
Other non-operating income, net | 35 | 4 | 89 | 8 | ||||
Interest expense | (202) | (227) | (623) | (674) | ||||
Operating income | 1,089 | 568 | 5,135 | 1,775 | ||||
Litigation and investigation costs | (9) | (14) | (18) | (28) | ||||
Net gains (losses) on sales, consolidation and deconsolidation of facilities | 348 | (1) | 2,906 | 12 | ||||
Impairment and restructuring charges, and acquisition-related costs | (19) | (47) | (75) | (84) | ||||
Depreciation and amortization | (209) | (224) | (625) | (654) | ||||
Adjusted EBITDA | $ | 978 | $ | 854 | $ | 2,947 | $ | 2,529 |
Net operating revenues | $ | 5,122 | $ | 5,066 | $ | 15,593 | $ | 15,169 |
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues | 9.2 | % | 2.0 | % | 18.5 | % | 2.4 | % |
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) | 19.1 | % | 16.9 | % | 18.9 | % | 16.7 | % |
2024 | ||||
(Dollars in millions) | Q3 | YTD | ||
Net cash provided by operating activities | $ | 1,045 | $ | 2,378 |
Purchases of property and equipment | (216) | (601) | ||
Free cash flow | $ | 829 | $ | 1,777 |
Net cash provided by investing activities | $ | 667 | $ | 3,801 |
Net cash used in financing activities | $ | (498) | $ | (3,313) |
Net cash provided by operating activities | $ | 1,045 | $ | 2,378 |
Less: | ||||
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (55) | (119) | ||
Adjusted net cash provided by operating activities | 1,100 | 2,497 | ||
Purchases of property and equipment | (216) | (601) | ||
Adjusted free cash flow | $ | 884 | $ | 1,896 |
2023 | ||||
(Dollars in millions) | Q3 | YTD | ||
Net cash provided by operating activities | $ | 503 | $ | 1,550 |
Purchases of property and equipment | (176) | (543) | ||
Free cash flow | $ | 327 | $ | 1,007 |
Net cash used in investing activities | $ | (169) | $ | (636) |
Net cash used in financing activities | $ | (214) | $ | (718) |
Net cash provided by operating activities | $ | 503 | $ | 1,550 |
Less: | ||||
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (27) | (105) | ||
Adjusted net cash provided by operating activities | 530 | 1,655 | ||
Purchases of property and equipment | (176) | (543) | ||
Adjusted free cash flow | $ | 354 | $ | 1,112 |
Fourth Quarter 2024 | FY 2024 | |||||||
(Dollars in millions, except per share amounts) | Low | High | Low | High | ||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 211 | $ | 311 | $ | 3,093 | $ | 3,193 |
Less: | ||||||||
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)
|
(57) | (7) | (150) | (100) | ||||
Net gains on sales, consolidation and deconsolidation of facilities(2)
|
- | - | 2,906 | 2,906 | ||||
Loss from early extinguishment of debt(2)
|
- | - | (8) | (8) | ||||
Tax and noncontrolling interests impact of above items | 10 | - | (745) | (755) | ||||
Adjusted net income available to common shareholders | $ | 258 | $ | 318 | $ | 1,090 | $ | 1,150 |
Diluted earnings per share | $ | 2.20 | $ | 3.24 | $ | 31.56 | $ | 32.58 |
Less: | ||||||||
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements
|
(0.59) | (0.07) | (1.53) | (1.02) | ||||
Net gains on sales, consolidation and deconsolidation of facilities | - | - | 29.65 | 29.65 | ||||
Loss from early extinguishment of debt | - | - | (0.08) | (0.08) | ||||
Tax and noncontrolling interests impact of above items | 0.10 | - | (7.60) | (7.70) | ||||
Adjusted diluted earnings per share | $ | 2.69 | $ | 3.31 | $ | 11.12 | $ | 11.73 |
Weighted average basic shares outstanding (in thousands) | 95,000 | 95,000 | 97,000 | 97,000 | ||||
Weighted average dilutive shares outstanding (in thousands) | 96,000 | 96,000 | 98,000 | 98,000 | ||||
(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
|
||||||||
(2) The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024.
|
Fourth Quarter 2024 | FY 2024 | |||||||
(Dollars in millions) | Low | High | Low | High | ||||
Net income available to Tenet Healthcare Corporation common shareholders | $ | 211 | $ | 311 | $ | 3,093 | $ | 3,193 |
Less: | ||||||||
Net income available to noncontrolling interests | (225) | (245) | (835) | (855) | ||||
Income tax expense | (84) | (114) | (1,185) | (1,215) | ||||
Interest expense | (207) | (197) | (830) | (820) | ||||
Loss from early extinguishment of debt(2)
|
- | - | (8) | (8) | ||||
Other non-operating income, net | 26 | 36 | 115 | 125 | ||||
Net gains on sales, consolidation and deconsolidation of facilities(2)
|
- | - | 2,906 | 2,906 | ||||
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)
|
(57) | (7) | (150) | (100) | ||||
Depreciation and amortization | (195) | (215) | (820) | (840) | ||||
Adjusted EBITDA | $ | 953 | $ | 1,053 | $ | 3,900 | $ | 4,000 |
Net income available to Tenet Healthcare Corporation common shareholders | $ | 211 | $ | 311 | $ | 3,093 | $ | 3,193 |
Net operating revenues | $ | 5,007 | $ | 5,207 | $ | 20,600 | $ | 20,800 |
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues | 4.2 | % | 6.0 | % | 15.0 | % | 15.4 | % |
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) | 19.0 | % | 20.2 | % | 18.9 | % | 19.2 | % |
(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
|
||||||||
(2) The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024.
|
FY 2024 | ||||
(Dollars in millions) | Low | High | ||
Net cash provided by operating activities | $ | 1,775 | $ | 2,125 |
Purchases of property and equipment | (800) | (900) | ||
Free cash flow | $ | 975 | $ | 1,225 |
Net cash provided by operating activities | $ | 1,775 | $ | 2,125 |
Less: | ||||
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1)
|
(175) | (125) | ||
Adjusted net cash provided by operating activities
|
1,950 | 2,250 | ||
Purchases of property and equipment | (800) | (900) | ||
Adjusted free cash flow(2)
|
$ | 1,150 | $ | 1,350 |
(1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
|
||||
(2) The Company's definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests. |